Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies - Summary - MDSpire

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies

  • By

  • Masashi Nishikubo

  • Yoshimitsu Shimomura

  • Ryusuke Yamamoto

  • Satoshi Yoshioka

  • Hayato Maruoka

  • Seiko Nasu

  • Tomomi Nishioka

  • Kenji Sakizono

  • Satoshi Mitsuyuki

  • Tomoyo Kubo

  • Naoki Okada

  • Daishi Nakagawa

  • Kimimori Kamijo

  • Hiroharu Imoto

  • Yuya Nagai

  • Nobuhiro Hiramoto

  • Noboru Yonetani

  • Tadakazu Kondo

  • Chisato Miyakoshi

  • Asako Doi

  • Takayuki Ishikawa

  • January 23, 2023

  • 0 min

Share

Objective:

To investigate humoral and cellular responses among patients recently treated with anti-CD20 antibodies after a third dose of mRNA COVID-19 vaccines administered at longer intervals, emphasizing the potential for improved immune response.

Key Findings:
  • Humoral responses increased from 15% before to 42% after the third vaccination in patients, indicating a significant improvement.
  • T-cell responses were observed in 30% of patients before and 51% after the third vaccination, highlighting the enhanced immune activation.
  • Overall, 72% of patients exhibited either humoral or cellular responses after the third vaccination, demonstrating the effectiveness of the booster.
Interpretation:

The study suggests that a longer interval between anti-CD20 antibody treatment and booster vaccination may enhance immune responses in patients with hematologic diseases, potentially informing future vaccination strategies.

Limitations:
  • Small sample size may limit generalizability, suggesting the need for larger studies to confirm findings.
  • Exclusion of patients with undocumented COVID-19 infection may affect results, as this could overlook potential confounding factors.
Conclusion:

The third dose of mRNA COVID-19 vaccines significantly improved humoral and cellular immune responses in patients treated with anti-CD20 antibodies, indicating the potential benefit of extended intervals between treatments and vaccinations, which could inform clinical practice.

Original Source(s)

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies

  • by Masashi Nishikubo, Yoshimitsu Shimomura, Ryusuke Yamamoto, Satoshi Yoshioka, Hayato Maruoka, Seiko Nasu, Tomomi Nishioka, Kenji Sakizono, Satoshi Mitsuyuki, Tomoyo Kubo, Naoki Okada, Daishi Nakagawa, Kimimori Kamijo, Hiroharu Imoto, Yuya Nagai, Nobuhiro Hiramoto, Noboru Yonetani, Tadakazu Kondo, Chisato Miyakoshi, Asako Doi, Takayuki Ishikawa

  • January 23, 2023

Related Content

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients